Lasmiditan (codenamed COL-144) is an investigational drug for the treatment of acute migraine. It was discovered by Eli Lilly and Company and is being developed by CoLucid Pharmaceuticals. Phase II clinical trial for dose finding purposes were completed in 2007 for an intravenous and in early 2010 for an oral application form.
This page contains content from the copyrighted Wikipedia article "Lasmiditan"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
